Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080806 | 0.90 | MMP3 (0.51) | PLA2G7SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL6943312 | 0.86 | PLA2G7 (0.43) | PLA2G7SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL7080541 | 0.82 | PLA2G7 (0.47) | PLA2G7SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL6952641 | 0.81 | MMP2 (0.44) | PLA2G7SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL6946802 | 0.78 | MMP2 (0.40) | PLA2G7SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL6948525 | 0.78 | PLA2G7 (0.54) | PLA2G7SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL6946069 | 0.77 | MMP2 (0.41) | PLA2G7SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL6952582 | 0.77 | MMP2 (0.38) | PLA2G7MMP2MMP9MMP3MMP13 | |
| SCHEMBL6948787 | 0.77 | PLA2G7 (0.53) | PLA2G7SMN1; SMN2MMP2MMP9MMP3 | |
| SCHEMBL6946800 | 0.77 | MMP2 (0.49) | PLA2G7SMN1; SMN2MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | PLA2G7 610/4885SMN1; SMN2 3038/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.